HIV Centers for Underrepresented Populations in Research Clinical Trials Unit (CURE CTU)

研究临床试验单位中代表性不足人群的艾滋病毒中心（CURE CTU）将 由美国大陆五家经验丰富且成功的临床研究中心（CRS）组成。 第六个新的CRS位于华盛顿的儿童国家医疗中心。每个CRS都有 >20年在孕妇、婴儿、儿童、青少年和儿童中开展临床研究的经验 感染艾滋病毒和有感染艾滋病毒风险的年轻人。每个HIV CURE CRS都位于48个县之一， 在华盛顿特区，美国总统提出的结束战争的倡议所针对的地理位置。 艾滋病毒流行病。CURE CTU管理层位于加州圣地亚哥大学; Stephen博士 A. Spector将担任主要研究者。这六个CRS位于贝勒学院， 医学/德克萨斯州休斯顿的德克萨斯儿童医院，Ann & Robert H.伊利诺伊州芝加哥卢里儿童医院， 西北大学、圣裘德儿童研究医院和田纳西大学卫生部 田纳西州孟菲斯科学中心、迈阿密大学、佛罗里达州迈阿密霍尔茨儿童医院、全国儿童医院 医学中心在华盛顿，DC，和加州大学，圣地亚哥，CA。治愈CTU是 唯一一个专门侧重于孕妇、妇女、儿童、青少年和 美国大陆25岁以下的年轻人通过NIAID资助。具体目标 解决NIAID提出的四个网络的许多目标高优先领域。目标1：确定 新的和持久的干预措施，以减少水库和控制艾滋病毒复制在没有抗逆转录病毒疗法（ART- 自由缓解）（ACTG目标1和IMPAACT目标2）。目标2：提高孕妇和产后妇女的抗逆转录病毒治疗水平 艾滋病毒感染者，以优化孕产妇和婴儿的健康结果，并加快评估（PK，安全性，抗病毒 有效性）、许可证发放以及孕妇、婴儿、儿童和 感染艾滋病毒的青少年（IMPAACT目标1）。目标3：设计和进行广泛中和抗体的研究 （bnAbs），单独和联合使用，以及长效抗逆转录病毒药物和暴露前给药系统 预防（PrEP）（ACTG目标2，HPTN目标1，IMPAACT目标1）。目的4：研究HIV疫苗的接种情况， 暴露和未暴露的婴儿诱导广泛的免疫应答，包括广泛中和抗体 (HVTN目标4）。具体目标5：设计和开展研究，以评价多用途预防技术 同时预防艾滋病毒和怀孕，性传播感染或阿片类药物依赖（HPTN Aim 2）。目的6：确定预防和管理并发症的最佳可行方法， 婴儿、儿童、青少年、孕妇和产后艾滋病毒感染的合并感染及其治疗 妇女（影响目标4）。目标7：预防或改善艾滋病毒相关非传染性合并症的治疗 发病率和评估治疗有/无HIV的人中的B型肝炎病毒感染的策略（ACTG目标4， HVTN目标1）。

The HIV Centers for Underrepresented Populations in Research Clinical Trials Unit (CURE CTU) will be comprised of five highly experienced and successful Clinical Research Sites (CRS) within the continental U.S. and a sixth new CRS located at Children’s National Medical Center in Washington, DC. Each of the CRSs has >20 years of experience conducting clinical research in pregnant women, infants, children, adolescents and young adults with and at-risk for HIV infection. Each of the HIV CURE CRSs is located in one of 48 counties or in Washington DC, geographic locations that have been targeted by the U.S. President’s initiative to end the HIV epidemic. The CURE CTU management is located at the University of California San Diego; Dr. Stephen A. Spector will serve as the Principal Investigator. The six CRSs are located at Baylor College of Medicine/Texas Children’s Hospital in Houston, TX, Ann & Robert H. Lurie Children’s Hospital of Chicago, IL, Northwestern University, St. Jude Children’s Research Hospital and the University of Tennessee Health Science Center in Memphis, TN, University of Miami, Holtz Children’s Hospital, Miami, FL, Children’s National Medical Center in Washington, DC, and the University of California, San Diego, CA. The CURE CTU is the only unit specifically focused on research in pregnant women, women, children, adolescents and young adults less than 25 years in the continental U.S. funded through NIAID. The Specific Aims address many of the targeted high priority areas of the four NIAID proposed Networks. Aim 1: Identify novel and durable interventions to reduce reservoirs and control HIV replication in the absence of ART (ART- free remission) (ACTG Aim 1 and IMPAACT Aim 2). Aim 2: Advance ART of pregnant and postpartum women with HIV, to optimize maternal and infant health outcomes, and accelerate the evaluation (PK, safety, antiviral efficacy), licensure and optimal use of potent and durable ARVs for pregnant women, infants, children and adolescents with HIV (IMPAACT Aim 1). Aim 3: Design and conduct studies of broadly neutralizing antibodies (bnAbs), alone and in combination, and long-acting antiretroviral agents and delivery systems for pre-exposure prophylaxis (PrEP) (ACTG Aim 2, HPTN Aim 1, IMPAACT Aim 1). Aim 4: To investigate vaccination of HIV- exposed and unexposed infants to induce broad immune responses including broadly neutralizing antibody (HVTN Aim 4). Specific Aim 5: Design and conduct studies to evaluate multipurpose prevention technologies that concurrently prevent HIV and pregnancy, sexually transmitted infections or opioid dependence (HPTN Aim 2). Aim 6: Determine optimal and feasible methods for the prevention and management of complications and co-infections of HIV infection and their treatment in infants, children, adolescents and pregnant and postpartum women (IMPAACT Aim 4). Aim 7: Prevent or improve the treatment of HIV-related non-infectious co- morbidities and evaluate strategies to cure hepatitis B virus infection in people with/without HIV (ACTG Aim 4, HVTN Aim 1).